Profarma Distribuidora de Produtos Farmaceuticos SA Statistics
Profarma Distribuidora de Produtos Farmaceuticos SA (PFRM3) Stock Statistics & Valuation Metrics
Total Valuation
Profarma Distribuidora de Produtos Farmaceuticos SA has a market cap or net worth of BRL 896.28M. The enterprise value is BRL 2.49B.
- Market Cap
- BRL 896.28M
- Enterprise Value
- BRL 2.49B
Share Statistics
Profarma Distribuidora de Produtos Farmaceuticos SA has 123,812,775 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 123,812,775
- Owned by Insiders
- ―
- Owned by Institutions
- 0.20%
Financial Efficiency
Profarma Distribuidora de Produtos Farmaceuticos SA’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 12.01%.
- Return on Equity (ROE)
- 0.09
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 12.01%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 1.62M
- Profits Per Employee
- 16.80K
- Employee Count
- 7,077
- Asset Turnover
- 1.84
- Inventory Turnover
- 4.63
Valuation Ratios
The current PE Ratio of Profarma Distribuidora de Produtos Farmaceuticos SA is 5.72. Profarma Distribuidora de Produtos Farmaceuticos SA’s PEG ratio is 0.18.
- PE Ratio
- 5.72
- PS Ratio
- 0.07
- PB Ratio
- 0.62
- Price to FCF
- 2.99
- Price to Operating Cash Flow
- 1.93
- PEG Ratio
- 0.18
Income Statement
In the last 12 months, Profarma Distribuidora de Produtos Farmaceuticos SA had revenue of 11.45B and earned 118.90M in profits. Earnings per share was 0.97.
- Revenue
- 11.45B
- Gross Profit
- 1.75B
- Operating Income
- 381.63M
- Pretax Income
- 117.46M
- Net Income
- 118.90M
- EBITDA
- 581.79M
- Earnings Per Share (EPS)
- 0.97
Cash Flow
In the last 12 months, operating cash flow was 460.53M and capital expenditures -163.48M, giving a free cash flow of 297.06M billion.
- Operating Cash Flow
- 460.53M
- Free Cash Flow
- 297.06M
- Free Cash Flow per Share
- 2.42
Dividends & Yields
Profarma Distribuidora de Produtos Farmaceuticos SA pays an annual dividend of ―, resulting in a dividend yield of 8.81%
- Dividend Per Share
- ―
- Dividend Yield
- 8.81%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 33.37%
- Earnings Yield
- 17.36%
Stock Price Statistics
- Beta
- 1.31
- 52-Week Price Change
- -11.50%
- 50-Day Moving Average
- 7.88
- 200-Day Moving Average
- 7.54
- Relative Strength Index (RSI)
- 46.06
- Average Volume (3m)
- 203.09K
Important Dates
Profarma Distribuidora de Produtos Farmaceuticos SA upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
Profarma Distribuidora de Produtos Farmaceuticos SA as a current ratio of 1.29, with Debt / Equity ratio of 104.17%
- Current Ratio
- 1.29
- Quick Ratio
- 0.69
- Debt to Market Cap
- 0.78
- Net Debt to EBITDA
- 2.01
- Interest Coverage Ratio
- 1.81
Taxes
In the past 12 months, Profarma Distribuidora de Produtos Farmaceuticos SA has paid -8.55M in taxes.
- Income Tax
- -8.55M
- Effective Tax Rate
- -0.07
Enterprise Valuation
Profarma Distribuidora de Produtos Farmaceuticos SA EV to EBITDA ratio is 3.75, with an EV/FCF ratio of 7.74.
- EV to Sales
- 0.18
- EV to EBITDA
- 3.75
- EV to Free Cash Flow
- 7.74
- EV to Operating Cash Flow
- 4.99
Balance Sheet
Profarma Distribuidora de Produtos Farmaceuticos SA has BRL 487.77M in cash and marketable securities with BRL 1.90B in debt, giving a net cash position of -BRL 1.41B billion.
- Cash & Marketable Securities
- BRL 487.77M
- Total Debt
- BRL 1.90B
- Net Cash
- -BRL 1.41B
- Net Cash Per Share
- -BRL 11.39
- Tangible Book Value Per Share
- BRL 8.03
Margins
Gross margin is 15.14%, with operating margin of 3.34%, and net profit margin of 1.24%.
- Gross Margin
- 15.14%
- Operating Margin
- 3.34%
- Pretax Margin
- 1.49%
- Net Profit Margin
- 1.24%
- EBITDA Margin
- 4.91%
- EBIT Margin
- 3.19%
Analyst Forecast
The average price target for Profarma Distribuidora de Produtos Farmaceuticos SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 13.20%
- EPS Growth Forecast
- 30.95%

